Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 0.88%.

  • Coherus Oncology's Return on Capital Employed fell 1200.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of 0.44% for FY2024, which is 4700.0% up from last year.
  • Latest data reveals that Coherus Oncology reported Return on Capital Employed of 0.88% as of Q3 2025, which was down 1200.0% from 0.67% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Capital Employed ranged from a high of 0.1% in Q1 2021 and a low of 1.28% during Q1 2024
  • For the 5-year period, Coherus Oncology's Return on Capital Employed averaged around 0.64%, with its median value being 0.65% (2022).
  • Per our database at Business Quant, Coherus Oncology's Return on Capital Employed tumbled by -7800bps in 2021 and then skyrocketed by 7100bps in 2025.
  • Coherus Oncology's Return on Capital Employed (Quarter) stood at 0.48% in 2021, then crashed by -41bps to 0.68% in 2022, then dropped by -9bps to 0.74% in 2023, then rose by 22bps to 0.58% in 2024, then crashed by -52bps to 0.88% in 2025.
  • Its last three reported values are 0.88% in Q3 2025, 0.67% for Q2 2025, and 0.58% during Q1 2025.